Inventiva shares fall 14.5% in a week, erasing their October rebound
The Burgundy-based biotech specialising in fibrotic and metabolic diseases declines mid-session, in a Paris market that is also sharply lower. The stock extends the decline begun earlier this week and ranks near the bottom of the index.
A stock that has slipped below its short-term averages after its October rebound
The Inventiva stock is down 3% at €3.07, after a 14.4% fall over the week that wipes out most of the rebound begun at the end of October. The stock now sits 7% below its MM20 and just 1.6% below its MM50, while the MM200 remains far away, more than 23% above the price.
The decline comes as the SBF 120 loses 1.22% and the stock ranks among the largest decliners in the index. The RSI at 46 remains neutral, indicating that this week's drop has not pushed the stock into oversold territory. A month earlier, the stock had gained 13.5%, and it retains those gains despite the recent slide.
Cash covered until the second quarter of 2027 and revenue expected on Monday
When it published its H1 2026 results on 29 July 2026, the company had indicated that its cash did not cover operating requirements for the next twelve months, with a horizon limited to the end of the second quarter of 2027 without additional financing. It had also recalled the €75 million financing transaction and the €103 million share offering announced on 2 June 2026.
The group recorded no revenue in the first half of 2026, compared with €4.5 million a year earlier. Its third-quarter revenue is expected on 23 November, the next date on the calendar.